Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.82 USD | -2.67% | -5.70% | -87.64% |
05-14 | Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating | MT |
05-09 | Transcript : Amylyx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.64% | 124M | |
+0.10% | 91.42B | |
+2.76% | 41.08B | |
-9.06% | 34.26B | |
+53.99% | 25.27B | |
-16.61% | 15.27B | |
-9.14% | 12.81B | |
-12.11% | 11.6B | |
-43.61% | 11.42B | |
+4.49% | 9.16B |
- Stock Market
- Equities
- AMLX Stock
- News Amylyx Pharmaceuticals, Inc.
- Goldman Sachs Upgrades Amylyx Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $49 From $45